Metropolitan Life Insurance Co. NY Boosts Stake in Flexion Therapeutics Inc (FLXN)

Metropolitan Life Insurance Co. NY lifted its position in Flexion Therapeutics Inc (NASDAQ:FLXN) by 341.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 10,455 shares of the specialty pharmaceutical company’s stock after buying an additional 8,084 shares during the period. Metropolitan Life Insurance Co. NY’s holdings in Flexion Therapeutics were worth $118,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. State Board of Administration of Florida Retirement System grew its holdings in shares of Flexion Therapeutics by 4.9% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 16,668 shares of the specialty pharmaceutical company’s stock worth $189,000 after acquiring an additional 772 shares during the last quarter. Carroll Financial Associates Inc. grew its holdings in shares of Flexion Therapeutics by 100.0% in the 4th quarter. Carroll Financial Associates Inc. now owns 2,000 shares of the specialty pharmaceutical company’s stock worth $26,000 after acquiring an additional 1,000 shares during the last quarter. Advisor Group Inc. grew its holdings in shares of Flexion Therapeutics by 68.2% in the 4th quarter. Advisor Group Inc. now owns 8,608 shares of the specialty pharmaceutical company’s stock worth $97,000 after acquiring an additional 3,490 shares during the last quarter. Commonwealth Equity Services LLC grew its holdings in shares of Flexion Therapeutics by 10.4% in the 4th quarter. Commonwealth Equity Services LLC now owns 42,365 shares of the specialty pharmaceutical company’s stock worth $479,000 after acquiring an additional 4,000 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. grew its holdings in shares of Flexion Therapeutics by 6.4% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 72,595 shares of the specialty pharmaceutical company’s stock worth $822,000 after acquiring an additional 4,356 shares during the last quarter. 94.73% of the stock is currently owned by institutional investors.

In other Flexion Therapeutics news, insider Michael D. Clayman purchased 4,046 shares of the stock in a transaction dated Tuesday, March 12th. The shares were acquired at an average price of $12.36 per share, for a total transaction of $50,008.56. Following the completion of the acquisition, the insider now owns 70,856 shares of the company’s stock, valued at approximately $875,780.16. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 14.59% of the company’s stock.

Shares of FLXN stock opened at $10.22 on Monday. Flexion Therapeutics Inc has a 1-year low of $9.90 and a 1-year high of $29.10. The company has a current ratio of 7.78, a quick ratio of 7.58 and a debt-to-equity ratio of 1.35. The firm has a market cap of $388.29 million, a PE ratio of -2.28 and a beta of 1.68.

A number of equities analysts recently issued reports on the company. Northland Securities restated a “buy” rating and issued a $20.00 target price on shares of Flexion Therapeutics in a report on Friday, March 1st. BidaskClub upgraded Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, January 31st. Zacks Investment Research cut Flexion Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, February 20th. Benchmark cut Flexion Therapeutics from a “buy” rating to a “hold” rating and set a $11.49 target price on the stock. in a report on Friday, January 4th. Finally, Needham & Company LLC restated a “buy” rating and issued a $36.00 target price (down from $42.00) on shares of Flexion Therapeutics in a report on Friday, January 4th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus price target of $22.64.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Baseball Daily News and is owned by of Baseball Daily News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.baseballdailydigest.com/news/2019/04/22/metropolitan-life-insurance-co-ny-boosts-stake-in-flexion-therapeutics-inc-flxn.html.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.

Featured Story: How to read a candlestick chart

Want to see what other hedge funds are holding FLXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Flexion Therapeutics Inc (NASDAQ:FLXN).

Institutional Ownership by Quarter for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.